Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on December 18, 2025. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the advancement of the Company's clinical development program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statement data.
Material Changes and Events
- Clinical Study Approval: The Institutional Review Board (IRB) at Emory University School of Medicine approved the initiation of a Phase 1b human challenge study for the Company's candidate, CDI-988.
- Study Objective: The study aims to evaluate CDI-988 as both a preventive measure and a treatment for norovirus infections.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the press release information is not deemed "filed" under Section 18 of the Exchange Act. The primary outlook is the commencement of the Phase 1b study.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific study design details and timelines.
- Confirm the status of the Company's cash runway and funding needs, as this filing does not address liquidity.
- Monitor subsequent filings for the actual start date of the Phase 1b study and any enrollment updates.
- Review the Company's latest 10-K or 10-Q for the most recent financial position and risk disclosures.